Market Overview:
Paclitaxel is a type of chemotherapy drug used to treat cancer. It is available as both a natural API and semi-synthetic API. The global paclitaxel market was valued at ,711 million in 2017 and is projected to reach ,814 million by 2030, growing at a CAGR of 8.4% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of cancer, rising demand for novel therapies, and increasing R&D investments in the field of oncology drugs. However, patent expirations for key marketed products may restrain the growth of this market during the forecast period. The global paclitaxel market can be segmented based on type (natural paclitaxel API and semi-synthetic paclitaxel API), application (ovarian cancer, cervical cancer, breast cancer, other), and region (North America, Latin America Europe Asia Pacific Middle East & Africa). In terms of type , the natural paclitaxel API segment is expected to grow at a higher CAGR during the forecast period owing to its benefits such as low toxicity levels and easy availability as compared to semi-syntheticpac lit ax elAPI .
Product Definition:
Paclitaxel is a chemotherapeutic agent used to treat cancer. It is a member of the taxane family of drugs and works by interfering with the cellular division process.
Natural Paclitaxel API:
Natural Paclitaxel API, also known as Aspleninib or NAPAPI is a novel oral drug developed by the pharmaceutical company Pfizer. It is an analog of paclitaxel, which is a type of taxane. Natural Paclitaxel API was granted breakthrough therapy approval by the FDA in September 2012 for treating non-small cell lung cancer (NSCLC).
Semi-synthetic Paclitaxel API:
Paclitaxel, a semi-synthetic form of paclitaxel is an antibody-drug conjugate used in the treatment of cancer. It's major action takes place when it binds with the tumor cell and then delivers a fatal blow to them. Paclitaxel was first developed by Burroughs Wellcome Ltd., now GlaxoSmithKline Pharmaceuticals Limited (GSK).
Application Insights:
Ovarian cancer accounted for the largest share in 2016 owing to the increasing prevalence of ovarian cancer and its growing demand globally. Paclitaxel is a well-tolerated drug with an excellent safety profile; it exhibits activity against both estrogen-sensitive and -resistant tumors with few doses. This property has led to its extensive use in treating advanced ovarian carcinoma, which has been growing at a significant rate over the past few years.
Breast cancer is expected to be one of the fastest-growing segments due largely to increased awareness about early detection among women aged 40 years and above, coupled with rising incidence rates globally since 1980s or earlier. The other segment that accounts for major share in global paclitaxel market includes lung, colorectal, kidney & bladder cancers as well as non-small cell lung carcinoma (NSCLC).
Regional Analysis:
Asia Pacific dominated the global paclitaxel market in 2017. The region is expected to maintain its dominance over the forecast period as well owing to increasing awareness about cancer and various other preventive measures taken up by the government. China, India, Japan, Australia and South Korea are some of the prominent markets in Asia Pacific that are anticipated to witness significant growth over the next eight years due to rising incidences of cancer coupled with growing R&D initiatives undertaken by key players for development of novel drugs.
In addition, availability of skilled professionals and improvement in healthcare infrastructure is also likely to drive regional growth during forecast period. In September 2016, Novartis AG announced an agreement with Takeda Pharmaceuticals Corporation for distribution partnership agreement which includes marketing & distribution alliance for Chinese medicines including Taxol (paclitaxel)in Japan under a brand name ‘Nuptixol’ since it was not approved yet by Japanese FDA (Food & Drug Administration).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the paclitaxel market. According to a study by American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in United States in 2017. This number is expected to rise in the coming years due to increase in aging population and unhealthy lifestyle habits.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another major growth driver for the paclitaxel market. Paclitaxel has been found to be effective against various types of cancers and hence its use as a monotherapy or combination therapy is increasing rapidly across the globe.
- Technological advancements: The technological advancements are also fuelling the growth of paclitaxel market globally as they are helping researchers and manufacturers develop better formulations and delivery methods of this drug which can improve its efficacy and safety profile significantly . For instance, development of nanoparticle-based delivery systems has helped reduce toxicity associated with administrationof this drug while improving its therapeutic index .
Scope Of The Report
Report Attributes
Report Details
Report Title
Paclitaxel Market Research Report
By Type
Natural Paclitaxel API, Semi-synthetic Paclitaxel API
By Application
Ovarian Cancer, Cervical Cancer, Breast Cancer, Other
By Companies
Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Paclitaxel Market Report Segments:
The global Paclitaxel market is segmented on the basis of:
Types
Natural Paclitaxel API, Semi-synthetic Paclitaxel API
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Cancer, Cervical Cancer, Breast Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Phyton
- ScinoPharm
- Novasep
- Samyang
- Polymed
- TAPI (Teva)
- Fresenius-kabi
- Huiang biopharma
- Southpharma
- Yunnan Hande
- Hainan Yew Pharm
- Jiangsu Yew Biotechnology
Highlights of The Paclitaxel Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Natural Paclitaxel API
- Semi-synthetic Paclitaxel API
- By Application:
- Ovarian Cancer
- Cervical Cancer
- Breast Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Paclitaxel Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Paclitaxel is a chemotherapy drug used to treat various types of cancer. It works by stopping the growth of cancer cells.
Some of the major players in the paclitaxel market are Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology.
The paclitaxel market is expected to grow at a compound annual growth rate of 8.4%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Paclitaxel Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Paclitaxel Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Paclitaxel Market - Supply Chain
4.5. Global Paclitaxel Market Forecast
4.5.1. Paclitaxel Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Paclitaxel Market Size (000 Units) and Y-o-Y Growth
4.5.3. Paclitaxel Market Absolute $ Opportunity
5. Global Paclitaxel Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Paclitaxel Market Size and Volume Forecast by Type
5.3.1. Natural Paclitaxel API
5.3.2. Semi-synthetic Paclitaxel API
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Paclitaxel Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Paclitaxel Market Size and Volume Forecast by Application
6.3.1. Ovarian Cancer
6.3.2. Cervical Cancer
6.3.3. Breast Cancer
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Paclitaxel Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Paclitaxel Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Paclitaxel Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Paclitaxel Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Paclitaxel Demand Share Forecast, 2019-2026
9. North America Paclitaxel Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Paclitaxel Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Paclitaxel Market Size and Volume Forecast by Application
9.4.1. Ovarian Cancer
9.4.2. Cervical Cancer
9.4.3. Breast Cancer
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Paclitaxel Market Size and Volume Forecast by Type
9.7.1. Natural Paclitaxel API
9.7.2. Semi-synthetic Paclitaxel API
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Paclitaxel Demand Share Forecast, 2019-2026
10. Latin America Paclitaxel Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Paclitaxel Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Paclitaxel Market Size and Volume Forecast by Application
10.4.1. Ovarian Cancer
10.4.2. Cervical Cancer
10.4.3. Breast Cancer
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Paclitaxel Market Size and Volume Forecast by Type
10.7.1. Natural Paclitaxel API
10.7.2. Semi-synthetic Paclitaxel API
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Paclitaxel Demand Share Forecast, 2019-2026
11. Europe Paclitaxel Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Paclitaxel Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Paclitaxel Market Size and Volume Forecast by Application
11.4.1. Ovarian Cancer
11.4.2. Cervical Cancer
11.4.3. Breast Cancer
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Paclitaxel Market Size and Volume Forecast by Type
11.7.1. Natural Paclitaxel API
11.7.2. Semi-synthetic Paclitaxel API
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Paclitaxel Demand Share, 2019-2026
12. Asia Pacific Paclitaxel Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Paclitaxel Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Paclitaxel Market Size and Volume Forecast by Application
12.4.1. Ovarian Cancer
12.4.2. Cervical Cancer
12.4.3. Breast Cancer
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Paclitaxel Market Size and Volume Forecast by Type
12.7.1. Natural Paclitaxel API
12.7.2. Semi-synthetic Paclitaxel API
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Paclitaxel Demand Share, 2019-2026
13. Middle East & Africa Paclitaxel Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Application
13.4.1. Ovarian Cancer
13.4.2. Cervical Cancer
13.4.3. Breast Cancer
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Type
13.7.1. Natural Paclitaxel API
13.7.2. Semi-synthetic Paclitaxel API
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Paclitaxel Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Paclitaxel Market: Market Share Analysis
14.2. Paclitaxel Distributors and Customers
14.3. Paclitaxel Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Phyton
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. ScinoPharm
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novasep
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Samyang
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Polymed
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. TAPI (Teva)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Fresenius-kabi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Huiang biopharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Southpharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Yunnan Hande
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hainan Yew Pharm
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Jiangsu Yew Biotechnology
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook